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Objectives: Bacillus Calmette-Gue´rin (BCG) vaccination has proven to be effi-
cient in immunologically naı¨ve infants; however, it has not been investigated
that maternal natural exposure to Mycobacterium and/or BCG vaccine could
influence the characteristics of immune responses to BCG in newborns. In this
study, we analyzed whether the maternal immune status to M tuberculosis (M tb)
can affect neonatal immunity to BCG using a mouse model.
Methods: Neonates were obtained from mice that were previously exposed to
live BCG, to live M avium, or to heat-killed M tb H37Rv, and from naı¨ve control
mothers. One week after birth, the neonates were divided into two subgroups:
one group immunized with live BCG via the subcutaneous route and the other
group of neonates sham-treated. Interferon-gamma (IFNg) secretion in response
to in vitro stimulation with heat-killed BCG or purified protein derivative (PPD)
was examined. Protection against M tb infection was evaluated by challenging
mice nasally with live M tb H37Rv followed by counting colonies from spleen and
lung homogenates.
Results: BCG-immunized neonates showed increased IFNg secretion in response
to heat-killed BCG or PPD. All mice in BCG-immunized neonates subgroups
showed reduced bacterial burden (colony forming unit) in the lungs when
compared with control naive neonate mice. However, no statistically significant
difference was observed when comparing BCG-immunized mice born from
mothers previously exposed to M avium or immunized with either heat-killed
H37Rv or live BCG and mice born from naı¨ve mothers.
Conclusion: Thematernal immune status toM tb does not appear to impact on the
immunogenicity of BCG vaccine in their progeny in our experimental conditions.ted under the terms of the Creative Commons Attribution Non-Commercial License (http://
) which permits unrestricted non-commercial use, distribution, and reproduction in any
operly cited.
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ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
Evaluation of maternal effect on BCG vaccine efficacy in neonates 691. Introduction 2. Materials and MethodsMycobacterium tuberculosis (M tb) is an intracellular
pathogen that causes severe infectious disease, tuber-
culosis (TB), which is responsible for high level of
mortality and morbidity [1e3]. About 30% of the pop-
ulation is worldwide infected with this infectious agent
[1]. Most of them are considered to have latent tuber-
culosis infection (LTBI) and only 10% of the infection
will develop to serious pulmonary TB [2,4]. Neverthe-
less, new cases of this bacterial infection are still
occurring mostly in developing countries, and immu-
nologically immature infants in these regions can be
easily exposed to infections with mycobacteria [5].
To prevent from TB infection, Bacillus of Calmette
and Gue´rin (BCG) obtained from a live attenuated
strain of M bovis (M bovis) has been used as an only
authorized vaccine since 1921 [6]. Previous study
showed outstanding effectiveness of BCG vaccination
at birth in control of neonatal miliary TB and meningitis
TB as well [7]. However, the vaccination with BCG
shows inconsistent responsiveness and relatively low
protection efficacy against predominant pulmonary TB
in adults [8]. In animal and human studies, neonatal
immunization with BCG showed relatively higher
protection efficacy than that in adults, which is medi-
ated by Th1-type immune responses [9,10].
Guirado and colleagues [11] reported that antibodies
play an essential protective role against mycobacterial
infections by passive immunization using sera obtained
from mice treated with detoxified M tb extracts in
B cell-deficient mice, while it is generally accepted that
cell-mediated immune response is important in
controlling M tb infections. While current BCG vaccine
has proven to be efficient in immunologically naı¨ve
infants, a maternal history of natural exposure to
mycobacteria or vaccination against TB has not been
studied yet. Therefore, we hypothesized that maternal
immune status to mycobacteria may play a critical role
in the uptake and subsequent protective immunoge-
nicity of BCG in newborns. In the present study, we
analyzed whether the maternal immune status to M tb
can affect the neonatal immunity to BCG in mouse
neonates by assessing in vitro IFNg secretion by
stimulated spleen cells [11e13] and by evaluating the
protective efficacy after challenge experiments. We
found that neonatal BCG immunization can reduce the
bacterial load in pulmonary tissues. In addition, we
showed that the maternal immune history mediated by
either vaccination or pre-exposure to M tb was insuf-
ficient to elicit the specific immune responses to BCG
vaccine in their progeny. This may provide basic
insights into importance of immunogenicity through
neonatal vaccination and/or maternal vaccination,
and it can be considered for further TB vaccine
researches.2.1. Animals
Six-weeks old female Balb/c mice (OrientBio or
Daehan Biolink, Korea) were maintained under specific
pathogen-free conditions in the animal facility, Inter-
national Vaccine Institute (Seoul, Korea), where they
were fed with sterilized food and water ad libitum.
Breeding cages were checked daily for new births, and
the pups were kept with the mother until weaning at 3
weeks of age. Animal infections with M tb were per-
formed at the Biosafety Level 3 facility of the institute.
All experiments described were approved by appropriate
institutional animal care and use committees.
2.2. Bacteria
M bovis BCG Pasteur (BCG) [14], M tuberculosis
H37Rv (M tb H37Rv) [15] and M avium subsp. Homi-
nissuis (M avium)[16] were cultured in suspension in
7H9 Middlebrook media (BD Bioscience, San Diego,
CA, USA) supplemented with 10% OADC (v/v, BD,
Franklin Lakes, NJ, USA) and 0.05% Tween80.
2.3. Vaccination of mice
One week before mating, mice were immunized with
live BCG [subcutaneously, 5 105 colony forming units
[CFU]), live M avium (intranasally, 1 105 CFU), or
heat-killed M tb H37Rv (intranasally, 5 105 CFU),
respectively. Neonates obtained from individual mothers
were divided into two subgroups and vaccinated 1 week
after birth: one group immunized with live BCG
(5 105 CFU) via subcutaneous route and the other
group of neonates sham-treated.
2.4. Antibody determination
Four weeks after BCG vaccination, immunoglobulin
G (IgG) level in serum obtained from individual mice
were analyzed by enzyme-linked immunosorbent assay
(ELISA). Briefly, ELISA plates were coated with heat-
inactivated BCG (5 105 CFU/mL) in phosphate buff-
ered saline (PBS) overnight at 4 C. Next day, plates
were washed four times with PBS-T (v/v, 0.05%
Tween20, Sigma-Aldrich, St. Louis, MO, USA) and
blocked with 1% bovine serum albumin (BSA) (Sigma-
Aldrich, St. Louis, MO, USA) for 1 hour at room
temperature. After washings, the samples were applied
in serial dilutions and subsequently incubated for 2
hours at room temperature. Following extensive wash-
ings with PBS-T, horseradish peroxidase-conjugated
goat anti-mouse IgG (Southern Biotech, Birmingham,
AL, USA) was diluted in 1% BSA and applied. After 1-
hour incubation at room temperature, the plates were
washed four times, and the 3,30, 5,500-tetramethylbenzi-
dine (TMB) peroxidase substrate (Moss, Inc., Pasadena,
MD, USA) was subsequently added to develop the
enzymatic color reaction. Optical density was detected
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70 J.S. Choi, et alby using a microplate reader (molecular device, Sun-
nyvale, CA, USA) at 450 nm, and concentrations were
given in inverse log2 at OD of 0.2.
2.5. M tb challenge of mice
Infection with M tb H37Rv was performed 4 weeks
after BCG immunization via intranasal route with an
inoculum of 200 CFU/20 ml per head. The mice were
sacrificed four weeks after challenge infection, and
bacterial loads in lung and spleen were determined by
incubating serial dilutions of lung and spleen homoge-
nates from individual mice on 7H11 Middlebrook agar
plates. The 7H11 Middlebrook agar plates were freshly
prepared with 100 mg/mL of ampicillin (Sigma-Aldrich,
St. Louis, MO, USA) and 10 mg/mL of fungizone
(Gibco, Grand Island, NY, USA). The plates were
incubated for 3e4 weeks at 37 C with 5% CO2, and the
numbers of bacterial colonies were counted.
2.6. Measurement of in vitro IFN g production
Specific IFNg response against heat-inactivated
BCG (10 minutes at 95 C) or purified protein deriva-
tive (PPD) (kindly provided by Institut Pasteur Korea)
was measured by ELISA. It was detected after in vitro
stimulation of splenocytes and lung cells obtained from
individual mice at 3 weeks or 4 weeks after neonatal
vaccination with BCG, respectively. Lung (5 105
cells/well) and/or spleen cells (2 105 cells/well) were
obtained from individual mice and stimulated with
either heat-killed BCG (5 105 CFU/mL) or PPD (5 mg/
mL) for 72 hours at 37 C with 5% CO2. Following
incubation, supernatants were harvested and stored at
e80 C until use. IFNg level was determined by using
mouse BD OptEIA IFNg ELISA kit (BD Bioscience,
San Diego, CA, USA) according to manufacturer’s
instructions.
2.7. Statistical analysis
All statistical analyses using the unpaired Student
t-test were performed in GraphPad Prism 5 (GraphPad
Software Inc., La Jolla, IL, USA). A p< 0.05 value was
considered statistically significant.C
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Figure 1. IgG level following vaccination with BCG. To
determine the optimum dose of BCG vaccine, we first quan-
tified the IgG level in serum in response to BCG vaccine by
enzyme-linked immunosorbent assay. One week after birth,
neonates (nZ 4 to 6 heads per each group) were subcutane-
ously primed with different doses of live BCG. Three weeks
after the BCG-priming, specific anti-BCG IgG level was
measured. Anti-BCG IgG production was detected solely in
mice vaccinated with 5 105 CFU of live BCG, Representa-
tive data are shown as reciprocal log2 Immunoglobulin G titer.
Data are mean SD. BCGZ Bacillus Calmette-Gue´rin;
CFUZ colony forming unit; IgGZ immunoglobulin G;
SCZ subcutaneous; SDZ standard deviation.3. Results
3.1. Determination of optimal subcutaneous
BCG inoculum
Although T cell-mediated immunity plays critical
roles in protection against M tb infection, antigen-
specific antibodies induced by successful vaccination
are thought to be also involved in modifying the course
of M tb infection. We first assessed humoral immune
response in response to BCG vaccination. Different
doses of live BCG, 1 102, 5 102, 1 104, and
5 105 CFU were subcutaneously administered into
1-week-old neonate mice and specific anti-BCG IgGtiter in serum was measured after 3 weeks of vaccina-
tion. Anti-BCG IgG production was detected solely in
mice vaccinated with 5 105 CFU of live BCG; this
dose was therefore used as a standard for further
immunizations in this study (Figure 1).3.2. Impact of maternal immune status on
in vitro IFNg production in neonates after
BCG immunization
We analyzed cellular immune responses of neonates
following BCG vaccination by measuring in vitro IFNg
secretion in response to BCG or PPD, since it has been
described that protective immune responses to M tb
infection is mainly mediated by T-cell immunity.
First, to compare different maternal immune back-
grounds, 6-week-old female mice were administered
with either live BCG subcutaneously, heat-inactivated
M tb H37Rv intranasally, live M avium intranasally, or
sham-treated, respectively. Mating occurred 1 week
later. Neonate mice born from mothers previously
exposed to above described mycobacteria were divided
into two subgroups; one group consisting of neonates
vaccinated with BCG at the age of 7 days and the other
group of neonates sham-treated (Figure 2). After 3
weeks, spleen and lung cells from naı¨ve and BCG
immunized neonates group born from either naı¨ve or
BCG immunized mothers were analyzed for IFNg
Maternal vaccination Neonatal BCG (s.c.) M.tb (i.n.)
1 k 3 k Neonates
Mating
 w 1 wk w s 4 wks
4
 w
k
s
CFU determination
Figure 2. Schedule for M tb study. For this study, female mice were subcutaneously primed with live BCG (5 105 CFU) or
heat-inactivated M tuberculosis H37Rv (5 105 CFU), respectively, while live M avium (1 105 CFU) was administered via
intranasal route. The female mice were mated with naı¨ve males a week later. When newborns obtained from each female mouse
were 1-week old, they were divided into two subgroups; naı¨ve and the BCG-vaccinated. For subsequent neonatal BCG vaccination,
live BCG (5 105 CFU) was given subcutaneously. Three weeks after the BCG vaccination, IFNg production by splenocytes and
lung cells was analyzed after in vitro stimulation with heat-inactivated BCG. Four weeks after BCG vaccination, the neonates were
intranasally challenged with 5 104 CFU of virulent M tuberculosis H37Rv. The mice infected with M tb were kept for 4 weeks at
the ABSL-3 facility, until sacrifice. Bacterial loads (CFU) in lung and spleen were subsequently quantified. BCGZ Bacillus
Calmette-Gue´rin; CFUZ colony forming unit; i.n.Z intranasal.
Evaluation of maternal effect on BCG vaccine efficacy in neonates 71secretion in response to BCG. No statistically significant
difference was observed when comparing subgroups of
BCG-immunized mice born from mothers previously
immunized with BCG or from naive mothers in both
tissues (Figure 3A and B).
Next, we examined splenic IFNg secretion in
response to PPD (Figure 3C). Statistically significant
difference was detected only between BCG immunized
progeny born from naı¨ve mothers and from BCG
immunized mothers (Figure 3). These results suggest
that neonatal BCG vaccination can elicit cellular
immune response regardless of maternal pre-exposure to
mycobacteria; however, maternal pre-exposure to BCG
can increase PPD-specific IFNg production in their
progeny.
3.3. Influence of maternal immunity on
protective efficacy of neonatal BCG
vaccination
We thereby performed M tb challenge experiment in
order to see whether different maternal immune status
can affect BCG vaccine efficacy in their progeny.
Intranasal M tb H37Rv challenge was performed after 4
weeks of BCG vaccination, and bacterial numbers were
determined from lung and spleen of individual mice
after 4 weeks of challenge (Figure 2).
When compared with nonvaccinated neonates,
neonates mice administered with BCG exhibit a signifi-
cant decrease of the bacterial loads in the lung following
M tb infection; however, there was no statistical signifi-
cance between BCG-immunized mice born from female
mice previously exposed to either heat-killedM tbH37Rv,
liveMavium, or live BCG, or naı¨vemothers. These results
suggest that maternal exposure to different M tb-related
antigens does not have impacts on neonatal immunoge-
nicity induced by BCG vaccination. No statisticallysignificant reduction of bacterial burden in the spleen
was observed in any of the groups. These results suggest
that the impact of maternal immunity on the protective
immunity induced by neonatal vaccination with BCG is
minimum.4. Discussion
In this study, the effect of maternal pre-exposure to
mycobacteria has been investigated on BCG vaccine
efficacy in neonates using a mouse model. We found
that maternal immune status to mycobacteria does not
impact on the protective immunogenicity of BCG
vaccine in their progeny under our experimental
conditions.
The main component of immune protection trans-
ferred from mother to child is antibody. Maternal anti-
body is transferred to the fetus and newborns across
the placenta using the neonatal Fc receptor and via
breast milk, respectively [17]. Unlike pigs, horses and
ruminants, which rely mainly on colostral transfer, mice
allow placental transfer of maternal immunoglobulin.
Therefore, neonatal mice can be applied as an alterna-
tive to human neonatal vaccination [17].
To generate enough quantity of antibodies, we first
determined the optimal subcutaneous BCG inoculums in
neonate and used the 5 105 CFU as a standard dose for
immunization (Figure 1). BCG-immunized neonates
showed increased IFNg secretion in response to BCG or
PPD. In vitro IFNg secretion in response to PPD from
splenocytes of BCG-immunized neonates born to BCG
vaccinated mother is higher than BCG-immunized
neonates born to naı¨ve mothers. This statistically signif-
icant difference might indicate that maternal pre-
exposure to BCG influences the neonates’
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Figure 3. Impact of maternal immune status on neonatal
IFNg production in response to BCG. Specific IFNg responses
against heat-inactivated BCG (A and B) or PPD (C) were
detected by in vitro stimulation using splenocytes and lung
cells obtained from individual mice (nZ 8 to 16 heads per
each group) either at 3 weeks or 4 weeks post neonatal
vaccination with BCG, respectively. There was no statistically
significant difference between groups. Data are mean SD.
*p< 0.05 (Student’s t-test). BZ Bacillus Calmette-Gue´rin
(BCG)-vaccinated; hk M tbZ heat-inactivated M tb H37Rv-
administered; M aviumZlive M avium-administered;
NZ naı¨ve; SDZ standard deviation.
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Figure 4. Bacterial burden in lung and spleen. Bacterial
numbers (CFUs) were determined 4 weeks after challenge with
virulent M tb H37Rv in lung and spleen (nZ 3 to 11 heads
per each group) of mice (Balb/c) primed with BCG vaccine
Data are shown as log10 CFU. Data are mean SD. *p< 0.05
(Student’s t-test) compared with the naı¨ve and BCG-
vaccinated neonates of each subgroup. **p< 0.01. BZ Ba-
cillus Calmette-Gue´rin (BCG)-vaccinated; CFUZ colony
forming unit; hk M tbZ heat-inactivated M tb H37Rv-
administered; M aviumZlive M avium-administered;
72 J.S. Choi, et alresponsiveness to PPD by an immune mechanism still
unknown. No statistical difference in protective efficacy
against M tb infections was observed suggesting that theincreased IFNg production by PPD-stimulated cells was
not sufficient to prevent the infection.
Protection against M tb infection was evaluated after
intranasal challenge with M tb H37Rv. BCG-immunized
mice were protected when compared to naive mice.
However, no statistically significant difference was
observed between BCG -immunized mice born from
mothers previously exposed/immunized with heat-killed
M tb H37Rv, BCG or M avium and mice born from
naive mothers (Figure 4).
In humans, multiple factors, for instance, environ-
mental and genetic background, nutritional and socio-
economic status, may affect the BCG efficacy [18,19].
Successful neonatal immunity achieved by vaccination
can effectively protect the high-risk population from M
tb infections. This study showed that the efficacy ofNZ naı¨ve; SDZ standard deviation.
Evaluation of maternal effect on BCG vaccine efficacy in neonates 73neonatal vaccination with BCG or with recently devel-
oped new BCG-based live vaccine against tuberculosis
might not be affected by maternal immunity transferred
to newborns in regions endemic for M tb or M avium.Acknowledgements
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